

**Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin)
Recombinant Antibody
Catalog # APR10183****Specification**

Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) - Product Information

Application	FC, E, FTA
Primary Accession	P20273
Reactivity	Rat, Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	151.97 KDa

Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) - Additional Information**Target/Specificity**
Siglec-2 / CD22**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
MMAE**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Storage**
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.**Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) - Protein Information****Name** CD22 {ECO:0000303|PubMed:1691828, ECO:0000312|HGNC:HGNC:1643}**Function**
Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

Cellular Location

Cell membrane; Single-pass type I membrane protein


Tissue Location

B-lymphocytes.


Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) - Images

Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) is more than 95%, determined by SEC-HPLC.



Immobilized human Siglec 2 / CD22, His Tag at 2 µg/mL can bind Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) \square EC50=0.008851 µg/mL